+44 20 8123 2220
info@marketpublishers.com

Gliosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/G605EB4BFD04EN.html
Date: May 2024
Pages: 134
Price: US$ 6,499.00 (Single User License)
ID: G605EB4BFD04EN

Abstracts

The 7 major gliosarcoma markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.38% during 2024-2034.

The gliosarcoma market has been comprehensively analyzed in IMARC's new report titled "Gliosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gliosarcoma is a rare and aggressive form of brain tumor that exhibits characteristics of both glioblastoma and sarcoma. It typically arises from the supportive tissue of the brain called glial cells, which provide structure and support to neurons. Some of the common symptoms associated with the ailment are persistent headaches, seizures, cognitive changes like memory loss or confusion, focal neurological deficits like weakness or sensory disturbances, personality changes, speech difficulties, etc. Various other indications may include visual disorders, nausea, vomiting, balance problems, changes in behavior or mood, etc. Diagnosing the condition involves a comprehensive evaluation that incorporates several diagnostic procedures and clinical assessments. The diagnostic process typically begins with neuroimaging techniques, including magnetic resonance imaging (MRI) or computed tomography (CT) scans, to visualize the brain and identify any abnormal masses or lesions. Once a suspicious lesion is identified, a biopsy is performed to confirm the diagnosis. Numerous advanced procedures, such as molecular profiling and genetic testing, may also be utilized to assess specific genetic alterations and molecular markers.

The increasing incidences of TP53 gene mutations, which can disrupt normal cell growth and division, thereby leading to the formation of tumors, are primarily driving the

+44 20 8123 2220
info@marketpublishers.com

gliosarcoma market. Furthermore, the inflating utilization of various immune checkpoint inhibitors, such as pembrolizumab or nivolumab, to stimulate the immune system and enhance anti-tumor responses is acting as another significant growth-inducing factor. Besides this, the escalating application of intensity-modulated radiation therapy, since it allows for precise delivery of radiation, thereby minimizing damage to surrounding healthy tissue, is also creating a positive outlook for the market. Additionally, the emerging popularity of several magnetic resonance imaging sequences, including diffusion-weighted imaging (DWI), perfusion imaging, spectroscopy, etc., that provide additional information about tumor characteristics, vascularity, and metabolism, is further bolstering the market growth. Moreover, the ongoing advancements in neurosurgical techniques, such as the introduction of fluorescence-guided resection and intraoperative imaging, which have improved the extent of tumor removal and increased the chances of achieving complete resection, are expected to drive the gliosarcoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the gliosarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gliosarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gliosarcoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany

+44 20 8123 2220
info@marketpublishers.com

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the gliosarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the gliosarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current gliosarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

+44 20 8123 2220
info@marketpublishers.com

Market Insights

How has the gliosarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the gliosarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the gliosarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of gliosarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of gliosarcoma by age across the seven major markets?
What is the number of prevalent cases () of gliosarcoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with gliosarcoma across the seven major markets?
What is the size of the gliosarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of gliosarcoma?
What will be the growth rate of patients across the seven major markets?

Gliosarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for gliosarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?

+44 20 8123 2220
info@marketpublishers.com

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gliosarcoma market?
What are the key regulatory events related to the gliosarcoma market?
What is the structure of clinical trial landscape by status related to the gliosarcoma market?
What is the structure of clinical trial landscape by phase related to the gliosarcoma market?
What is the structure of clinical trial landscape by route of administration related to the gliosarcoma market?

+44 20 8123 2220
info@marketpublishers.com

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 GLIOSARCOMA - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 GLIOSARCOMA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 GLIOSARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights

+44 20 8123 2220
info@marketpublishers.com

7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)

+44 20 8123 2220
info@marketpublishers.com

7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 GLIOSARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 GLIOSARCOMA - UNMET NEEDS

10 GLIOSARCOMA - KEY ENDPOINTS OF TREATMENT

11 GLIOSARCOMA - MARKETED PRODUCTS

11.1 List of Gliosarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.

+44 20 8123 2220
info@marketpublishers.com

12 GLIOSARCOMA - PIPELINE DRUGS

12.1 List of Gliosarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 ERC 1671 - Epitopoietic Research Corporation
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Pembrolizumab- Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. GLIOSARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. GLIOSARCOMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 GLIOSARCOMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Gliosarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Gliosarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States

+44 20 8123 2220
info@marketpublishers.com

15.3.1 Gliosarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Gliosarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Gliosarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Gliosarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Gliosarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Gliosarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Gliosarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Gliosarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Gliosarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Gliosarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Gliosarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Gliosarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Gliosarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Gliosarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Gliosarcoma - Access and Reimbursement Overview

+44 20 8123 2220
info@marketpublishers.com

15.8 Market Scenario - Spain
15.8.1 Gliosarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Gliosarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Gliosarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Gliosarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Gliosarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Gliosarcoma - Access and Reimbursement Overview

16 GLIOSARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 GLIOSARCOMA MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 GLIOSARCOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Gliosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/G605EB4BFD04EN.html

Price: US$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G605EB4BFD04EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com